Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
1(17%)
Results Posted
50%(2 trials)

Phase Distribution

Ph phase_3
2
33%
Ph not_applicable
1
17%
Ph phase_2
3
50%

Phase Distribution

0

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
2(33.3%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(4)
Other(1)

Detailed Status

Completed4
unknown1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (50.0%)
Phase 32 (33.3%)
N/A1 (16.7%)

Trials by Status

unknown117%
recruiting117%
completed467%

Recent Activity

1 active trials
Showing 5 of 6
recruitingphase_2

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

NCT07340541
completedphase_3

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

NCT01546987
completednot_applicable

A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes

NCT02069730
unknownphase_3

Early Rising PSA Endocrine Treatment Versus Chemo-endocrine Therapy- SPCG14

NCT03119857
completedphase_2

Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer

NCT00283803
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07340541Phase 2

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

Recruiting
NCT01546987Phase 3

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Completed
NCT02069730Not Applicable

A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes

Completed
NCT03119857Phase 3

Early Rising PSA Endocrine Treatment Versus Chemo-endocrine Therapy- SPCG14

Unknown
NCT00283803Phase 2

Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer

Completed
NCT00006359Phase 2

Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6